Literature DB >> 31779288

Prevalence of High-Burden Medical Conditions Among Young and Middle-Aged Adults With Pediatric-Onset Medical Conditions: Findings From US Private and Public Administrative Claims Data.

Daniel G Whitney1.   

Abstract

Adults with pediatric-onset medical conditions (POMCs) are susceptible to early development of high-burden medical conditions. However, research pertaining to this topic is lacking, which is vital information that could assist in health benefit planning and administration. The purpose of this study was to determine the prevalence of high-burden medical conditions among privately and publicly insured adults with POMCs, as compared to adults without POMCs, from the US. Data from 2016 were extracted from Optum Clinformatics® Data Mart (private insurance) and a random 20% sample from Medicare fee-for-service (public insurance). International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes were used to identify 18-64-year-old beneficiaries with POMCs, as well as several high-burden medical conditions, including pain, fracture, mood affective disorders, anxiety disorders, ischemic heart diseases, cerebrovascular diseases, hypertensive and other cardiovascular diseases, type 2 diabetes, osteoporosis, osteoarthritis, chronic obstructive pulmonary diseases, liver diseases, and cancer. Privately and publicly insured adults with POMCs had higher prevalence of all medical conditions compared to adults without POMCs. Publicly insured adults with POMCs had higher prevalence of all medical conditions compared to privately insured adults with POMCs, except for the lower prevalence of pain and cancer. When stratified by the category of POMCs (eg, musculoskeletal, circulatory), privately and publicly insured groups tended to have higher prevalence of most (private) or all (public) medical conditions compared to adults without POMCs. Adults with POMCs have higher prevalence of several high-burden medical conditions compared to adults without POMCs. This health disparity was present regardless of insurance coverage, but was generally more pronounced for public vs. private insured adults with POMCs.
© 2019 The Author(s); Published by Kerman University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Entities:  

Keywords:  Clinical Epidemiology; Noncommunicable Diseases; Pediatric-Onset Medical Conditions; United States

Mesh:

Year:  2019        PMID: 31779288      PMCID: PMC6885858          DOI: 10.15171/ijhpm.2019.62

Source DB:  PubMed          Journal:  Int J Health Policy Manag        ISSN: 2322-5939


Background

Noncommunicable diseases are growing public health issues,[1] and represent a considerable source for early mortality[2] and economic burden.[3] The burden of noncommunicable diseases may disproportionally affect populations with disabilities, especially if the disability originated in childhood. Pediatric-onset medical conditions (POMCs) refer to a group of congenital or acquired conditions that originate at any point from conception through adolescence, and consist of impairments in behavioral, emotional, mental, intellectual, or physical function, or are associated with altered development or abnormal physiological processes. Very little clinical and research attention has been given to individuals with POMCs as they become adults, despite the anticipated growth of the adult population with POMCs.[4] Importantly, individuals with POMCs have complicated healthcare needs throughout the lifespan. This increases risk for early development of high-burden medical conditions, which refer to conditions that lead to high financial cost, excess morbidity, early mortality, or poor quality of life, and include pain, fracture, and noncommunicable diseases.[5-8] Therefore, a comprehensive understanding of the clinical epidemiology of high-burden medical conditions among young and middle-aged adults with POMCs is needed. Such information could inform healthcare policy-makers and clinical practice guidelines that promote early and cost-effective care for the aging population with POMCs. This study sought to inform these efforts by providing recent US national level estimates of the prevalence of several high-burden medical conditions for adults with POMCs that have private or public health insurance, as compared to adults without POMCs. We hypothesized that adults with POMCs would have higher prevalence of all high-burden medical conditions compared to adults without POMCs. We also hypothesized that this disparity would be greater for publicly insured adults with POMCs than privately insured adults with POMCs.

Methods

Data Sources

Data for this study were extracted from private and public administrative claims data from the year 2016. Optum Clinformatics® Data Mart Database (OptumInsightTM, Eden Prairie, MN, USA) provided de-identified information for privately insured beneficiaries (commercial or Medicare Advantage plans). A random 20% sample of the Medicare fee-for-service database provided de-identified information for publicly insured beneficiaries.

Sample Selection

Beneficiaries that were 18 to 64 years of age, had 12 full months of continuous enrollment, and had at least one medical service utilization in 2016 were included. Medicare beneficiaries were excluded if they were covered by Health Maintenance Organization plans because of incomplete claims. Medical diagnoses of all POMCs and medical conditions were identified using the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes, and are presented in Table S1 (see Supplementary file 1). A single claim in any position (medical file in Optum; inpatient, outpatient, and carrier file in Medicare) for POMCs was used to identify these beneficiaries. The single claim-based definition has shown good accuracy for identifying pediatric-onset conditions using administrative claims data, with sensitivity of 99% and positive predictive value of 79%.[9] It is not possible to determine if some POMCs developed in childhood or adulthood (eg, spinal cord injury) using a single year of claims data. Therefore, only conditions with known childhood origins were included. These conditions were then grouped into the following POMC subcategories: musculoskeletal system; neurodevelopmental; circulatory system; nervous system; genital organs; other chromosomal abnormalities; urinary system; respiratory and digestive systems; and malformations of the eye, ear, face, and neck. Beneficiaries of private insurance without any medical claims for POMCs represented the group without POMCs. The group without POMCs were ascertained through Optum to enhance representativeness of the sample of adults without POMCs, because criteria for enrollment in Medicare under 65 years of age requires permanent disability.

Medical Conditions

Prevalent medical conditions were ascertained using the same procedure to identify POMCs. Medical conditions were selected with guidance from the literature on disease, disability, and mortality,[1,2,5,10-12] and included pain, all-cause fracture, and several noncommunicable diseases: mood affective disorders; anxiety disorders; ischemic heart diseases; cerebrovascular diseases; hypertensive and other cardiovascular diseases; type 2 diabetes mellitus; osteoporosis; osteoarthritis; chronic obstructive pulmonary diseases; chronic kidney diseases; liver diseases; and malignant cancer anywhere in the body.

Participant Characteristics

Data on age and gender were extracted as they were reported in the same manner from Optum and Medicare. Other confounding variables were not considered for covariate adjustment to limit bias for reasons such as they had not been reported in both data sources (eg, education level), they had not been reported in the same manner (eg, race), or they had missing data on over 20% of the group (eg, income).

Statistical Analysis

All measures were summarized using SAS version 9.4 (SAS Institute, Inc., Cary, NC). Data were presented for adults without POMCs and with POMCs stratified by insurance coverage (private, public). Then, data were presented for adults with POMCs after stratifying by each POMC category for private and public insured beneficiaries. 95% CIs were calculated for the POMC groups. A sensitivity analysis was performed to determine prevalence estimates of medical conditions, but with the requirement of having at least 2 claims from separate days for each POMC and medical condition category.

Results

Participant characteristics for adults without POMCs (n = 5 415 475) and adults with POMCs that had private (n = 121 446) or public (n = 119 654) insurance is presented in Table 1. There were differences in the prevalence of POMC categories between private and public insurance. Notably, the publicly insured group had considerably (>3 times) higher prevalence of neurodevelopmental POMCs and considerably (>3 times) lower prevalence of POMCs of the genital organs compared to the privately insured group.
Table 1

Characteristics and Prevalence of High-Burden Medical Conditions Among Adults With and Without POMCs

Without POMCs With POMCs With POMCs
Private Insurance (n = 5 415 475) Private Insurance (n = 121 446) Public Insurance (n = 119 654)
Descriptive characteristics Point estimatePoint estimatePoint estimate
Age, mean (SD)43.8 (12.9)44.3 (13.6)46.9 (11.9)
18-40 years, %40.344.130.9
41-64 years, %59.755.969.1
Gender, %
Female53.855.646.8
Male46.244.453.2
POMC categories, %
Musculoskeletal system 27.610.8
Neurodevelopmental 14.156.7
Circulatory system 20.19.4
Nervous system 9.118.6
Genital organs 5.10.9
Other chromosomal abnormalities 4.59.6
Urinary system 10.35.9
Respiratory and digestive system 10.04.0
Malformation of eye, ear, face, or neck 4.82.1

Abbreviations: POMCs, pediatric-onset medical conditions; SD, standard deviation.

Note: Individuals may have more than one POMC and can be represented across multiple POMC categories.

Abbreviations: POMCs, pediatric-onset medical conditions; SD, standard deviation. Note: Individuals may have more than one POMC and can be represented across multiple POMC categories. Prevalence of high-burden medical conditions among adults with and without POMCs is presented in Table 2. Privately and publicly insured adults with POMCs had higher prevalence of all medical conditions compared to adults without POMCs. Publicly insured adults with POMCs had higher prevalence of all medical conditions compared to privately insured adults with POMCs, except for the lower prevalence of pain and cancer.
Table 2

Prevalence of High-Burden Medical Conditions Among Adults With and Without POMCs

Without POMCs With POMCs With POMCs
Private Insurance (n = 5415475) Private Insurance (n = 121446) Public Insurance (n = 119654)
% % (95% CI) % (95% CI)
Pain30.145.2 (44.9, 45.5)42.6 (42.3, 42.9)
Fracture2.65.2 (5.1, 5.3)7.8 (7.6, 8.0)
Mood affective disorders11.020.8 (20.6, 21.0)41.2 (40.9, 41.5)
Anxiety disorders15.125.5 (25.3, 25.7)37.9 (37.6, 38.2)
Ischemic heart diseases3.58.7 (8.5, 8.9)11.4 (11.2, 11.6)
Cerebrovascular diseases1.56.3 (6.2, 6.4)8.6 (8.4, 8.8)
Hypertensive and other cardiovascular diseases25.437.8 (37.5, 38.1)50.6 (50.3, 50.9)
Type 2 diabetes10.014.5 (14.3, 14.7)24.9 (24.7, 25.1)
Osteoporosis1.33.4 (3.3, 3.5)7.4 (7.3, 7.5)
Osteoarthritis7.715.8 (15.6, 16.0)19.3 (19.1, 19.5)
Chronic obstructive pulmonary disease0.71.8 (1.7, 1.9)12.0 (11.8, 12.2)
Chronic kidney disease1.86.6 (6.5, 6.7)11.4 (11.2, 11.6)
Liver diseases2.97.3 (7.2, 7.4)8.2 (8.0, 8.4)
Cancer3.86.6 (6.5, 6.7)5.9 (5.8, 6.0)

Abbreviation: POMCs, pediatric-onset medical conditions.

Abbreviation: POMCs, pediatric-onset medical conditions. Prevalence of high-burden medical conditions for each of the 9 POMC categories is presented in Table 3. Compared to adults without POMCs, most categories of POMCs from the privately insured group (7 to 9 categories) tended to have higher prevalence of all medical conditions. Compared to adults without POMCs, most categories of POMCs from the publicly insured group (8 to 9 categories) tended to have higher prevalence of all medical conditions. Finally, compared to the privately insured group of adults with POMCs, the publicly insured group had higher prevalence of all high-burden medical conditions for each POMC category, except for the similar or lower prevalence between neurodevelopmental POMCs for cerebrovascular diseases, POMCs of the nervous system for pain, ischemic heart diseases, cerebrovascular diseases, liver diseases, and cancer, and POMCs of other chromosomal abnormalities for pain, liver diseases, and cancer.
Table 3

High-Burden Medical Conditions Among Adults (18-64 Years) Stratified by the Category of POMCs

Musculoskeletal System Neurodevelopmental Circulatory System Nervous System Genital Organs Chromosomal Abnormalities Urinary System Respiratory Digestive Systems Eye, Ear, Face, or Neck
Sample size, n
Private insurance33 56617 14924 39311 0216164551812 47712 1905811
Public insurance12 91067 79111 27622 276107011 431699847442454
Pain, % (95% CI)
Private insurance63.4 (62.9, 63.9)27.8 (27.1, 28.5)39.8 (39.2, 40.4)46.0 (45.1, 46.9)31.9 (30.7, 33.1)27.2 (26.0, 28.4)47.3 (46.4, 48.2)45.3 (44.4, 46.2)34.4 (33.2, 35.6)
Public insurance74.1 (73.3, 74.9)31.8 (31.4, 32.2)55.2 (54.3, 56.1)39.1 (38.5, 39.7)56.7 (53.7, 59.7)25.7 (24.9, 26.5)62.8 (61.7, 63.9)66.6 (65.3, 67.9)45.1 (43.1, 47.1)
Fracture, % (95% CI)
Private insurance7.7 (7.4, 8.0)4.8 (4.5, 5.1)4.1 (3.9, 4.3)5.7 (5.3, 6.1)2.3 (1.9, 2.7)3.6 (3.1, 4.1)4.5 (4.1, 4.9)4.7 (4.3, 5.1)3.5 (3.0, 4.0)
Public insurance12.2 (11.6, 12.8)7.3 (7.1, 7.5)8.6 (8.1, 9.1)7.5 (7.2, 7.8)7.9 (6.3, 9.5)5.2 (4.8, 5.6)9.0 (8.3, 9.7)10.1 (9.2, 11.0)7.5 (6.5, 8.5)
Mood affective disorders, % (95% CI)
Private insurance19.2 (18.8, 19.6)35.4 (34.7, 36.1)18.3 (17.8, 18.8)24.7 (23.9, 25.5)13.5 (12.6, 14.4)13.7 (12.8, 14.6)18.8 (18.1, 19.5)20.6 (19.9, 21.3)14.5 (13.6, 15.4)
Public insurance44.2 (43.3, 45.1)45.1 (44.7, 45.5)39.7 (38.8, 40.6)30.8 (30.2, 31.4)45.4 (42.4, 48.4)22.1 (21.3, 22.9)39.8 (38.7, 40.9)48.7 (47.3, 50.1)34.4 (32.5, 36.3)
Anxiety disorders, % (95% CI)
Private insurance24.2 (23.7, 24.7)37.0 (36.3, 37.7)24.1 (23.6, 24.6)27.1 (26.3, 27.9)20.1 (19.1, 21.1)18.7 (17.7, 19.7)23.6 (22.9, 24.3)26.6 (25.8, 27.4)19.0 (18.0, 20.0)
Public insurance42.8 (41.9, 43.7)39.9 (39.5, 40.3)39.8 (38.9, 40.7)29.0 (28.4, 29.6)44.2 (41.2, 47.2)23.0 (22.2, 23.8)39.8 (38.7, 40.9)49.4 (48.0, 50.8)31.8 (30.0, 33.6)
Ischemic heart diseases, % (95% CI)
Private insurance5.4 (5.2, 5.6)4.7 (4.4, 5.0)19.9 (19.4, 20.4)5.6 (5.2, 6.0)2.9 (2.5, 3.3)3.2 (2.7, 3.7)10.9 (10.4, 11.4)8.4 (7.9, 8.9)4.4 (3.9, 4.9)
Public insurance14.7 (14.1, 15.3)6.8 (6.6, 7.0)33.8 (32.9, 34.7)5.8 (5.5, 6.1)14.5 (12.4, 16.6)4.4 (4.0, 4.8)26.9 (25.9, 27.9)21.7 (20.5, 22.9)11.1 (9.9, 12.3)
Cerebrovascular diseases, % (95% CI)
Private insurance3.1 (2.9, 3.3)6.2 (5.8, 6.6)15.0 (14.6, 15.4)7.9 (7.4, 8.4)1.7 (1.4, 2.0)2.8 (2.4, 3.2)5.5 (5.1, 5.9)4.0 (3.7, 4.3)2.9 (2.5, 3.3)
Public insurance9.0 (8.5, 9.5)6.2 (6.0, 6.4)24.7 (23.9, 25.5)7.7 (7.3, 8.1)8.6 (6.9, 10.3)4.3 (3.9, 4.7)13.7 (12.9, 14.5)11.9 (11.0, 12.8)6.1 (5.2, 7.0)
Hypertensive and other cardiovascular diseases, % (95% CI)
Private insurance32.2 (31.7, 32.7)32.3 (31.6, 33.0)49.0 (48.4, 49.6)35.8 (34.9, 36.7)19.5 (18.5, 20.5)21.1 (20.0, 22.2)57.7 (56.8, 58.6)40.1 (39.2, 41.0)28.8 (27.6, 30.0)
Public insurance59.3 (58.5, 60.1)45.4 (45.0, 45.8)71.4 (70.6, 72.2)42.4 (41.8, 43.0)58.6 (55.6, 61.6)28.8 (28.0, 29.6)83.4 (82.5, 84.3)67.2 (65.9, 68.5)50.3 (48.3, 52.3)
Type 2 diabetes, % (95% CI)
Private insurance12.9 (12.5, 13.3)16.7 (16.1, 17.3)15.7 (15.2, 16.2)12.7 (12.1, 13.3)7.7 (7.0, 8.4)11.7 (10.9, 12.5)18.9 (18.2, 19.6)15.1 (14.5, 15.7)14.3 (13.4, 15.2)
Public insurance28.9 (28.1, 29.7)23.0 (22.7, 23.3)33.5 (32.6, 34.4)15.5 (15.0, 16.0)32.2 (29.4, 35.0)17.2 (16.5, 17.9)37.1 (36, 38.2)33.3 (32.0, 34.6)28.9 (27.1, 30.7)
Osteoporosis, % (95% CI)
Private insurance4.0 (3.8, 4.2)3.1 (2.8, 3.4)2.9 (2.7, 3.1)4.3 (3.9, 4.7)1.0 (0.8, 1.2)3.6 (3.1, 4.1)3.6 (3.3, 3.9)4.4 (4.0, 4.8)2.2 (1.8, 2.6)
Public insurance11.0 (10.5, 11.5)7.3 (7.1, 7.5)7.4 (6.9, 7.9)10.9 (10.5, 11.3)6.7 (5.2, 8.2)7.5 (7.0, 8.0)8.0 (7.4, 8.6)10.5 (9.6, 11.4)7.1 (6.1, 8.1)
Osteoarthritis, % (95% CI)
Private insurance25.1 (24.6, 25.6)9.4 (9.0, 9.8)13.6 (13.2, 14.0)14.1 (13.5, 14.7)6.0 (5.4, 6.6)7.6 (6.9, 8.3)15.9 (15.3, 16.5)15.9 (15.3, 16.5)9.8 (9.0, 10.6)
Public insurance40.0 (39.2, 40.8)13.7 (13.4, 14.0)26.0 (25.2, 26.8)15.5 (15.0, 16.0)26.5 (23.9, 29.1)12.2 (11.6, 12.8)29.2 (28.1, 30.3)32.5 (31.2, 33.8)20.3 (18.7, 21.9)
Chronic obstructive pulmonary disease, % (95% CI)
Private insurance1.4 (1.3, 1.5)1.2 (1.0, 1.4)2.6 (2.4, 2.8)1.6 (1.4, 1.8)0.7 (0.5, 0.9)0.9 (0.7, 1.1)2.4 (2.1, 2.7)2.7 (2.4, 3.0)1.1 (0.8, 1.4)
Public insurance18.0 (17.3, 18.7)8.6 (8.4, 8.8)24.0 (23.2, 24.8)7.5 (7.2, 7.8)15.1 (13.0, 17.2)4.5 (4.1, 4.9)21.1 (20.1, 22.1)27.1 (25.8, 28.4)11.5 (10.2, 12.8)
Chronic kidney disease, % (95% CI)
Private insurance3.2 (3.0, 3.4)5.1 (4.8, 5.4)6.4 (6.1, 6.7)4.3 (3.9, 4.7)2.3 (1.9, 2.7)4.0 (3.5, 4.5)27.7 (26.9, 28.5)5.3 (4.9, 5.7)3.3 (2.8, 3.8)
Public insurance11.6 (11.0, 12.2)6.7 (6.5, 6.9)21.5 (20.7, 22.3)5.7 (5.4, 6.0)15.5 (13.3, 17.7)6.8 (6.3, 7.3)57.2 (56.0, 58.4)18.2 (17.1, 19.3)11.3 (10.0, 12.6)
Liver diseases, % (95% CI)
Private insurance4.9 (4.7, 5.1)4.3 (4.0, 4.6)7.5 (7.2, 7.8)4.6 (4.2, 5.0)4.0 (3.5, 4.5)4.6 (4.0, 5.2)17.2 (16.5, 17.9)15.4 (14.8, 16.0)4.3 (3.8, 4.8)
Public insurance10.1 (9.6, 10.6)5.8 (5.6, 6.0)13.5 (12.9, 14.1)5.2 (4.9, 5.5)12.7 (10.7, 14.7)5.0 (4.6, 5.4)22.1 (21.1, 23.1)22.9 (21.7, 24.1)7.1 (6.1, 8.1)
Cancer, % (95% CI)
Private insurance5.2 (5.0, 5.4)3.5 (3.2, 3.8)7.1 (6.8, 7.4)5.4 (5.0, 5.8)4.6 (4.1, 5.1)5.7 (5.1, 6.3)11.9 (11.3, 12.5)10.5 (10.0, 11.0)6.6 (6.0, 7.2)
Public insurance7.7 (7.2, 8.2)4.0 (3.9, 4.1)9.1 (8.6, 9.6)4.4 (4.1, 4.7)10.7 (8.8, 12.6)3.4 (3.1, 3.7)14.1 (13.3, 14.9)13.2 (12.2, 14.2)7.3 (6.3, 8.3)

Abbreviation: POMCs, pediatric-onset medical conditions.

Note: Individuals may have more than one POMC and can be represented across multiple POMC categories.

Abbreviation: POMCs, pediatric-onset medical conditions. Note: Individuals may have more than one POMC and can be represented across multiple POMC categories. The results of the sensitivity analysis requiring at least two claims from different days for each category of POMCs and medical conditions are presented in Table S2 for adults with and without POMCs and Table S3 after stratifying by the type of POMC category (see Supplementary file 1). Interpretations were unchanged for adults with and without POMCs. Interpretations were largely unchanged for most categories of POMCs from the privately and publicly insured group compared to controls.

Discussion

The chief finding here is that young and middle-aged adults with POMCs had higher prevalence of several high-burden medical conditions compared to adults without POMCs. While this was evident for both privately and publicly insured adults with POMCs, these health disparities were more pronounced for the publicly insured group with POMCs. These are critical findings, because these high-burden medical conditions are major contributors to the global and national burden of disease and mortality,[2,13-15] and are typically associated with advanced aging. Further, many of these high-burden medical conditions can be prevented, delayed, or better managed to reduce patient and caregiver burden. Taken together, these findings highlight the need for earlier clinical, rehabilitative, and healthcare policy efforts to improve awareness and access to quality healthcare, such as screening strategies, for these populations to allow for earlier detection of these high-burden medical conditions. In the current study, we also found that adults with POMCs of a particular biological system may be at greater risk of high-burden medical conditions of that same biological system. Notably, POMCs of the musculoskeletal system had the highest prevalence of fracture, osteoporosis, and osteoarthritis; POMCs of the circulatory system had the highest prevalence of ischemic heart diseases, cerebrovascular diseases, and hypertensive and other cardiovascular diseases; and POMCs of the urinary system had the highest prevalence of chronic kidney diseases. This information could assist clinical care for adults with POMCs, by allowing clinicians to target preventative and rehabilitation care specific to the needs of their patients with POMCs. This information could also assist in health benefit planning, by allowing administrators to allocate healthcare resources based on the POMC demographics of health plans. A major strength of the current study is the large sample of adults with POMCs from both private and public insurance databases, thus enhancing external validity.[16] Gathering data on clinical populations can be challenging, and little is known about the healthful aging process for individuals with POMCs across the lifespan. Another major strength of this study is the comprehensive assessment of several high-burden medical conditions, with many representing major contributors to the global and national burden of disease and mortality.[2,13-15] The present findings are robust and could improve clinical care and inform new research examining health disparities and healthcare delivery for individuals with POMCs. The limitations must be discussed. First, while Optum and Medicare databases are nationwide, Optum coverage is more predominant in Southern and Western regions of the United States, which may bias estimates because of regional differences in chronic disease prevalence.[17] Second, the primary analysis used a single claim to identify beneficiaries with POMCs and medical conditions. While validation studies have shown that at least 2 claims for a medical condition improves ability to identify beneficiaries with that medical condition,[9,18] single claim-based algorithms have been reported to have moderate-to-high positive predictive value (~80%) to detect POMCs,[9] or specificity up to 96% to detect a variety of medical conditions;[19,20] however, the accuracy of identifying conditions using claims data depends on the length of the study period[19] and the medical condition examined.[9,19-21] In light of this, a sensitivity analysis was performed that used at least two claims from different days to identify all POMCs and medical conditions. The results revealed the same conclusions as the primary analysis. When taken together, given the short study period of 12 months, the selected methodology to identify medical conditions using a single claim is likely sufficient to detect that the current data is evidence of health disparities among adults with POMCs, as compared to adults without POMCs. Third, the present study excluded individuals that did not have service utilization in 2016, which may have biased results. However, these excluded individuals that had insurance coverage may be somewhat healthy since they did not require a medical encounter in 2016, thus potentially biasing results in the present study to be more conservative estimates. Fourth, it is not possible using claims-based data from a single year to determine if certain conditions developed in childhood or later in life (eg, spinal cord injury, cancer, depression). Fifth, data were from a single year and longer study periods and longitudinal research designs could provide more robust findings and implications for research, practice, and policy. Lastly, the present study presented descriptive statistics rather than inferential statistics, and therefore did not account for potential confounding factors, such as indicators of socioeconomic status.

Conclusion

Adults with POMCs have higher prevalence of several high-burden medical conditions compared to adults without POMCs. This health disparity was present for both private and public insurance coverage, but was generally more pronounced for public vs. private insured adults with POMCs. Study findings are critical, because many of these high-burden medical conditions are associated with advanced aging, and may be prevented, delayed, or better managed with adequate clinical knowledge. These findings highlight the need for clinical and public health strategies to implement earlier detection and preventive medical services for noncommunicable diseases and other high-burden medical conditions for adult populations with POMCs. Future research is needed to examine how these high-burden medical condition profiles associate with mortality and quality of life for adults with POMCs.

Ethical issues

Since data are de-identified, consent to participate was not required and the University IRB approved this study as non-regulated.

Competing interests

Author declares that he has no competing interests.

Author’s contribution

DGW is the single author of the paper. Supplementary file 1 contains Tables S1-S3. Click here for additional data file.
  19 in total

Review 1.  Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.

Authors:  Harvey A Whiteford; Louisa Degenhardt; Jürgen Rehm; Amanda J Baxter; Alize J Ferrari; Holly E Erskine; Fiona J Charlson; Rosana E Norman; Abraham D Flaxman; Nicole Johns; Roy Burstein; Christopher J L Murray; Theo Vos
Journal:  Lancet       Date:  2013-08-29       Impact factor: 79.321

2.  Measuring antidepressant prescribing practice in a health care system using administrative data: implications for quality measurement and improvement.

Authors:  E A Kerr; E A McGlynn; K A Van Vorst; S L Wickstrom
Journal:  Jt Comm J Qual Improv       Date:  2000-04

3.  Adults with Cerebral Palsy have Higher Prevalence of Fracture Compared with Adults Without Cerebral Palsy Independent of Osteoporosis and Cardiometabolic Diseases.

Authors:  Daniel G Whitney; Andrea I Alford; Maureen J Devlin; Michelle S Caird; Edward A Hurvitz; Mark D Peterson
Journal:  J Bone Miner Res       Date:  2019-03-06       Impact factor: 6.741

Review 4.  The risk, burden, and management of non-communicable diseases in cerebral palsy: a scoping review.

Authors:  Jennifer M Ryan; Elizabeth Allen; John Gormley; Edward A Hurvitz; Mark D Peterson
Journal:  Dev Med Child Neurol       Date:  2018-03-24       Impact factor: 5.449

5.  Medicare beneficiaries with depression: comparing diagnoses in claims data with the results of screening.

Authors:  Katia Noyes; Hangsheng Liu; Jeffrey M Lyness; Bruce Friedman
Journal:  Psychiatr Serv       Date:  2011-10       Impact factor: 3.084

6.  The contribution of neurologic disorders to the national prevalence of depression and anxiety problems among children and adolescents.

Authors:  Daniel G Whitney; Danielle N Shapiro; Seth A Warschausky; Edward A Hurvitz; Mark D Peterson
Journal:  Ann Epidemiol       Date:  2018-11-15       Impact factor: 3.797

7.  Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Authors: 
Journal:  Lancet       Date:  2018-11-08       Impact factor: 79.321

8.  Validation of a case definition for depression in administrative data against primary chart data as a reference standard.

Authors:  Chelsea Doktorchik; Scott Patten; Cathy Eastwood; Mingkai Peng; Guanmin Chen; Cynthia A Beck; Nathalie Jetté; Tyler Williamson; Hude Quan
Journal:  BMC Psychiatry       Date:  2019-01-07       Impact factor: 3.630

9.  Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Authors: 
Journal:  Lancet       Date:  2017-09-16       Impact factor: 79.321

10.  Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Christopher J L Murray; Theo Vos; Rafael Lozano; Mohsen Naghavi; Abraham D Flaxman; Catherine Michaud; Majid Ezzati; Kenji Shibuya; Joshua A Salomon; Safa Abdalla; Victor Aboyans; Jerry Abraham; Ilana Ackerman; Rakesh Aggarwal; Stephanie Y Ahn; Mohammed K Ali; Miriam Alvarado; H Ross Anderson; Laurie M Anderson; Kathryn G Andrews; Charles Atkinson; Larry M Baddour; Adil N Bahalim; Suzanne Barker-Collo; Lope H Barrero; David H Bartels; Maria-Gloria Basáñez; Amanda Baxter; Michelle L Bell; Emelia J Benjamin; Derrick Bennett; Eduardo Bernabé; Kavi Bhalla; Bishal Bhandari; Boris Bikbov; Aref Bin Abdulhak; Gretchen Birbeck; James A Black; Hannah Blencowe; Jed D Blore; Fiona Blyth; Ian Bolliger; Audrey Bonaventure; Soufiane Boufous; Rupert Bourne; Michel Boussinesq; Tasanee Braithwaite; Carol Brayne; Lisa Bridgett; Simon Brooker; Peter Brooks; Traolach S Brugha; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Geoffrey Buckle; Christine M Budke; Michael Burch; Peter Burney; Roy Burstein; Bianca Calabria; Benjamin Campbell; Charles E Canter; Hélène Carabin; Jonathan Carapetis; Loreto Carmona; Claudia Cella; Fiona Charlson; Honglei Chen; Andrew Tai-Ann Cheng; David Chou; Sumeet S Chugh; Luc E Coffeng; Steven D Colan; Samantha Colquhoun; K Ellicott Colson; John Condon; Myles D Connor; Leslie T Cooper; Matthew Corriere; Monica Cortinovis; Karen Courville de Vaccaro; William Couser; Benjamin C Cowie; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Manu Dahiya; Nabila Dahodwala; James Damsere-Derry; Goodarz Danaei; Adrian Davis; Diego De Leo; Louisa Degenhardt; Robert Dellavalle; Allyne Delossantos; Julie Denenberg; Sarah Derrett; Don C Des Jarlais; Samath D Dharmaratne; Mukesh Dherani; Cesar Diaz-Torne; Helen Dolk; E Ray Dorsey; Tim Driscoll; Herbert Duber; Beth Ebel; Karen Edmond; Alexis Elbaz; Suad Eltahir Ali; Holly Erskine; Patricia J Erwin; Patricia Espindola; Stalin E Ewoigbokhan; Farshad Farzadfar; Valery Feigin; David T Felson; Alize Ferrari; Cleusa P Ferri; Eric M Fèvre; Mariel M Finucane; Seth Flaxman; Louise Flood; Kyle Foreman; Mohammad H Forouzanfar; Francis Gerry R Fowkes; Marlene Fransen; Michael K Freeman; Belinda J Gabbe; Sherine E Gabriel; Emmanuela Gakidou; Hammad A Ganatra; Bianca Garcia; Flavio Gaspari; Richard F Gillum; Gerhard Gmel; Diego Gonzalez-Medina; Richard Gosselin; Rebecca Grainger; Bridget Grant; Justina Groeger; Francis Guillemin; David Gunnell; Ramyani Gupta; Juanita Haagsma; Holly Hagan; Yara A Halasa; Wayne Hall; Diana Haring; Josep Maria Haro; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Hideki Higashi; Catherine Hill; Bruno Hoen; Howard Hoffman; Peter J Hotez; Damian Hoy; John J Huang; Sydney E Ibeanusi; Kathryn H Jacobsen; Spencer L James; Deborah Jarvis; Rashmi Jasrasaria; Sudha Jayaraman; Nicole Johns; Jost B Jonas; Ganesan Karthikeyan; Nicholas Kassebaum; Norito Kawakami; Andre Keren; Jon-Paul Khoo; Charles H King; Lisa Marie Knowlton; Olive Kobusingye; Adofo Koranteng; Rita Krishnamurthi; Francine Laden; Ratilal Lalloo; Laura L Laslett; Tim Lathlean; Janet L Leasher; Yong Yi Lee; James Leigh; Daphna Levinson; Stephen S Lim; Elizabeth Limb; John Kent Lin; Michael Lipnick; Steven E Lipshultz; Wei Liu; Maria Loane; Summer Lockett Ohno; Ronan Lyons; Jacqueline Mabweijano; Michael F MacIntyre; Reza Malekzadeh; Leslie Mallinger; Sivabalan Manivannan; Wagner Marcenes; Lyn March; David J Margolis; Guy B Marks; Robin Marks; Akira Matsumori; Richard Matzopoulos; Bongani M Mayosi; John H McAnulty; Mary M McDermott; Neil McGill; John McGrath; Maria Elena Medina-Mora; Michele Meltzer; George A Mensah; Tony R Merriman; Ana-Claire Meyer; Valeria Miglioli; Matthew Miller; Ted R Miller; Philip B Mitchell; Charles Mock; Ana Olga Mocumbi; Terrie E Moffitt; Ali A Mokdad; Lorenzo Monasta; Marcella Montico; Maziar Moradi-Lakeh; Andrew Moran; Lidia Morawska; Rintaro Mori; Michele E Murdoch; Michael K Mwaniki; Kovin Naidoo; M Nathan Nair; Luigi Naldi; K M Venkat Narayan; Paul K Nelson; Robert G Nelson; Michael C Nevitt; Charles R Newton; Sandra Nolte; Paul Norman; Rosana Norman; Martin O'Donnell; Simon O'Hanlon; Casey Olives; Saad B Omer; Katrina Ortblad; Richard Osborne; Doruk Ozgediz; Andrew Page; Bishnu Pahari; Jeyaraj Durai Pandian; Andrea Panozo Rivero; Scott B Patten; Neil Pearce; Rogelio Perez Padilla; Fernando Perez-Ruiz; Norberto Perico; Konrad Pesudovs; David Phillips; Michael R Phillips; Kelsey Pierce; Sébastien Pion; Guilherme V Polanczyk; Suzanne Polinder; C Arden Pope; Svetlana Popova; Esteban Porrini; Farshad Pourmalek; Martin Prince; Rachel L Pullan; Kapa D Ramaiah; Dharani Ranganathan; Homie Razavi; Mathilda Regan; Jürgen T Rehm; David B Rein; Guiseppe Remuzzi; Kathryn Richardson; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Felipe Rodriguez De Leòn; Luca Ronfani; Robin Room; Lisa C Rosenfeld; Lesley Rushton; Ralph L Sacco; Sukanta Saha; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; David C Schwebel; James Graham Scott; Maria Segui-Gomez; Saeid Shahraz; Donald S Shepard; Hwashin Shin; Rupak Shivakoti; David Singh; Gitanjali M Singh; Jasvinder A Singh; Jessica Singleton; David A Sleet; Karen Sliwa; Emma Smith; Jennifer L Smith; Nicolas J C Stapelberg; Andrew Steer; Timothy Steiner; Wilma A Stolk; Lars Jacob Stovner; Christopher Sudfeld; Sana Syed; Giorgio Tamburlini; Mohammad Tavakkoli; Hugh R Taylor; Jennifer A Taylor; William J Taylor; Bernadette Thomas; W Murray Thomson; George D Thurston; Imad M Tleyjeh; Marcello Tonelli; Jeffrey A Towbin; Thomas Truelsen; Miltiadis K Tsilimbaris; Clotilde Ubeda; Eduardo A Undurraga; Marieke J van der Werf; Jim van Os; Monica S Vavilala; N Venketasubramanian; Mengru Wang; Wenzhi Wang; Kerrianne Watt; David J Weatherall; Martin A Weinstock; Robert Weintraub; Marc G Weisskopf; Myrna M Weissman; Richard A White; Harvey Whiteford; Natasha Wiebe; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Sean R M Williams; Emma Witt; Frederick Wolfe; Anthony D Woolf; Sarah Wulf; Pon-Hsiu Yeh; Anita K M Zaidi; Zhi-Jie Zheng; David Zonies; Alan D Lopez; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

View more
  6 in total

1.  Effect of pain on mood affective disorders in adults with cerebral palsy.

Authors:  Daniel G Whitney; Sarah Bell; Daniel Whibley; Wilma M A Van der Slot; Edward A Hurvitz; Heidi J Haapala; Mark D Peterson; Seth A Warschausky
Journal:  Dev Med Child Neurol       Date:  2020-05-10       Impact factor: 5.449

2.  Excess healthcare spending associated with fractures among adults with cerebral palsy.

Authors:  Daniel G Whitney; Michelle S Caird; Karl J Jepsen; Edward A Hurvitz; Richard A Hirth
Journal:  Disabil Health J       Date:  2022-03-10       Impact factor: 4.615

3.  The mortality burden of non-trauma fracture for adults with cerebral palsy.

Authors:  Daniel G Whitney; Sarah Bell; Edward A Hurvitz; Mark D Peterson; Michelle S Caird; Karl J Jepsen
Journal:  Bone Rep       Date:  2020-10-07

4.  Advanced CKD Among Adults With Cerebral Palsy: Incidence and Risk Factors.

Authors:  Daniel G Whitney; Andrea L Oliverio; Neil S Kamdar; Benjamin L Viglianti; Abhijit Naik; Mary Schmidt
Journal:  Kidney Med       Date:  2020-08-06

5.  Incidence Rate of Advanced Chronic Kidney Disease Among Privately Insured Adults with Neurodevelopmental Disabilities.

Authors:  Daniel G Whitney; Mary Schmidt; Sarah Bell; Hal Morgenstern; Richard A Hirth
Journal:  Clin Epidemiol       Date:  2020-02-27       Impact factor: 4.790

6.  The Effect of Osteoporosis Medication on Risk Attenuation of Non-Trauma Fracture Among Adults with Cerebral Palsy: A Propensity Score-Matched Observational Study.

Authors:  Daniel G Whitney; Edward A Hurvitz; Michelle S Caird
Journal:  Clin Epidemiol       Date:  2021-02-12       Impact factor: 4.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.